tenofovir alafenamide (Vemlidy)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Hepatitis B

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
CN
  • Chronic hepatitis B in adults and adolescents aged 12 years and older weighing at least 35 kg (Vemlidy 25 mg)
Product first approved 2018gilead.com
EU
  • Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1).
Product first approved 2017EMA
JP
  • Suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication (Vemlidy 25 mg)
Product first approved 2016gilead.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (12)
Chronic Hepatitis B
NCT02836236 · Gilead Sciences
2015-06-19 – 2023-09-18 · HBV, Chronic HBV Infection
What this study did
NCT02836249 · Gilead Sciences
2015-06-19 – 2023-08-31 · HBV, Chronic HBV Infection
What this study did
NCT03887702 · SWOG Cancer Research Network
2020-01-17 – 2022-12-20 · Hepatitis B Infection, Malignant Solid Neoplasm
What this study did
Entecavir to TAF Switchactive not recruiting
NCT03489239 · Thomas Jefferson University
2017-11-16 – 2020-09-16 · Hepatitis B
What this study did
Other / comorbidity
NCT07792096 · University College, London
2026-11 – 2029-12 · HIV Infection
What this study did
NCT04937881 · University of California, Los Angeles
2022-06-13 – 2023-09-01 · Hiv
What this study did
NCT03122262 · Professor Francois Venter
2017-01-16 – 2022-07-29 · HIV-1 Infection
What this study did
Phase 2/3 (1)
Chronic Hepatitis B
NCT07203118 · Xi'an Xintong Pharmaceutical Research Co.,Ltd.
2025-07-01 – 2030-02-28 · Chronic Hepatitis B
What this study did
Phase 2 (20)
Chronic Hepatitis B
NCT06589518 · Jongman Kim
2025-03-01 – 2026-06-30 · Hepatitis B Virus, Liver Transplant, Renal Insufficiency
What this study did
NCT04535544 · Janssen Research & Development, LLC
2020-09-17 – 2025-03-05 · Hepatitis D, Chronic
What this study did
NCT04891770 · Gilead Sciences
2021-08-14 – 2024-07-19 · Chronic Hepatitis B
What this study did
NCT05275023 · Janssen Research & Development, LLC
2022-06-30 – 2024-05-31 · Hepatitis B, Chronic
What this study did
NCT03804372 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2020-07-07 – 2024-05-22 · Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
What this study did
NCT04585789 · Janssen Research & Development, LLC
2021-03-11 – 2024-01-09 · Hepatitis B
What this study did
NCT04667104 · Janssen Research & Development, LLC
2021-02-01 – 2023-04-17 · Hepatitis B, Chronic
What this study did
NCT05005507 · Janssen Research & Development, LLC
2021-11-03 – 2021-12-29 · Hepatitis B, Chronic
What this study did
NCT04059198 · F-star Therapeutics, Inc.
2019-10-10 – 2020-04-02 · Hepatitis B, HBV, Hepatitis B, Chronic
What this study did
NCT03115736 · Insel Gruppe AG, University Hospital Bern
2017-05-23 – 2019-12-05 · HIV and Hepatitis B Coinfection
What this study did
Other / comorbidity
NCT05652478 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-09-24 – 2030-01-31 · Healthy Volunteer, Weight Gain, Metabolic Effects, Integrase Strand Transfer Inhibitors
What this study did
NCT05467553 · National Taiwan University Hospital
2023-02-24 – 2025-08-31 · Hepatitis D
What this study did
NCT04880577 · Massachusetts General Hospital
2022-09-15 – 2025-02-14 · Multiple Sclerosis, Relapsing-Remitting, Fatigue
What this study did
NCT04143594 · Gilead Sciences
2019-11-22 – 2023-09-19 · HIV-1-infection
What this study did
Phase 1/2 (2)
Chronic Hepatitis B
NCT06150014 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-12-07 – 2026-09 · Chronic Hepatitis b
What this study did
Other / comorbidity
NCT00036634 · Gilead Sciences
2002-03 – 2003-02 · HIV Infections
What this study did
Phase 1 (21)
Chronic Hepatitis B
NCT07553767 · Ningbo No.2 Hospital
2026-03-31 – 2035-12-31 · Hepatocellular Carcinoma, HEPATITIS B CHRONIC, Hepatitis B Chronic Infection
What this study did
NCT07946757 · Xiamen Amoytop Biotech Co., Ltd.
2026-12-31 – 2027-12 · Chronic Hepaititis B
What this study did
NCT07295873 · Beijing Continent Pharmaceutical Co, Ltd.
2026-03-15 – 2026-05-29 · Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)
What this study did
NCT05550519 · Janssen Pharmaceutica N.V., Belgium
2022-10-31 – 2025-08-28 · Hepatitis B, Chronic
What this study did
NCT06592300 · Humanis Saglık Anonim Sirketi
2024-07-06 – 2024-09-13 · Chronic Hepatitis B in Adults and Paediatric Patients
What this study did
NCT05123599 · Janssen Research & Development, LLC
2021-12-06 – 2024-06-26 · Hepatitis B, Chronic
What this study did
NCT05423106 · Janssen Research & Development, LLC
2022-07-04 – 2023-03-20 · Healthy, Hepatitis B, Chronic
What this study did
NCT04906109 · Dong-A ST Co., Ltd.
2021-07-12 – 2021-10-05 · Hepatitis B
What this study did
NCT04507607 · Third Affiliated Hospital, Sun Yat-Sen University
2020-08-01 – 2021-06-30 · Chronic Hepatitis B, Mother-to-child Block, Antiviral Treatment
What this study did
NCT04551261 · Sunshine Lake Pharma Co., Ltd.
2021-01-10 – 2021-03-12 · Chronic Hepatitis B
What this study did
NCT02296853 · Gilead Sciences
2014-12-22 – 2015-04-17 · Hepatitis B Virus
What this study did
Other / comorbidity
NCT06274398 · Eastern Virginia Medical School
2024-01-16 – 2025-05-16 · Safety Issues
What this study did
NCT06087913 · Eastern Virginia Medical School
2023-11-08 – 2024-12-02 · Safety Issues
What this study did
NCT07002268 · Henan Genuine Biotech Co., Ltd.
2022-03-14 – 2023-08-31 · Healthy
What this study did
NCT02437110 · National Institute of Neurological Disorders and Stroke (NINDS)
2019-04-01 – 2023-05-09 · Amyotrophic Lateral Sclerosis
What this study did
NCT03510468 · National Institutes of Health Clinical Center (CC)
2018-06-12 – 2022-12-21 · Healthy Volunteers
What this study did
NCT04047420 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-12-11 – 2021-04-07 · HIV Infections
What this study did
NCT03762772 · CONRAD
2018-12-10 – 2019-03-20 · Hiv, HSV
What this study did
Phase 4 (33)
Chronic Hepatitis B
NCT03753074 · Young-Suk Lim
2019-02-18 – 2031-12-31 · Chronic Hepatitis b
What this study did
NCT03933384 · Taichung Veterans General Hospital
2019-08-19 – 2030-12-31 · Hepatitis B, Viral Hepatitis
What this study did
TAF vs TDF During the Pregancyenrolling by invitation
NCT07542951 · The Third Affiliated Hospital of Guangzhou Medical University
2024-12-27 – 2029-12-01 · Hepatitis B Virus Infection; Pregnant Women
What this study did
NCT07258251 · The Task Force for Global Health
2026-01-01 – 2028-12-31 · Chronic Hepatitis B, Hepatitis B Virus Infection
What this study did
NCT07668934 · The Third Affiliated Hospital of Guangzhou Medical University
2025-03-31 – 2028-03-30 · Hepatitis B Infection, Pregnant Women, Early Pregnancy
What this study did
NCT04939441 · Jidong Jia
2021-04-20 – 2027-12-31 · Chronic Hepatitis B
What this study did
NCT05410496 · Taichung Veterans General Hospital
2021-06-22 – 2027-07-30 · Safety Issues, Chronic Hepatitis B, Transplant Recipient
What this study did
NCT06221657 · Yonsei University
2024-02-01 – 2026-12-31 · Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication
What this study did
NCT04496882 · National Taiwan University Hospital
2020-09-09 – 2026-12-31 · Chronic Hepatitis b, Hepatitis B Reactivation
What this study did
NCT04674423 · National Cheng-Kung University Hospital
2020-05-14 – 2025-12-31 · Chronic Hepatitis b
What this study did
NCT05853718 · First People's Hospital of Hangzhou
2021-05-06 – 2025-12-30 · Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
What this study did
NCT04619082 · Chiayi Christian Hospital
2021-07-01 – 2024-12-31 · Hepatitis B Reactivation
What this study did
NCT03356834 · Humanity and Health Research Centre
2017-12-01 – 2024-10-31 · Chronic Hepatitis B
What this study did
NCT05177926 · Nanfang Hospital, Southern Medical University
2021-04-04 – 2023-12-31 · Hepatitis B, Chronic, Mother to Child Transmission
What this study did
NCT04201808 · New Discovery LLC
2021-05-01 – 2023-09-30 · Hepatitis B, Chronic
What this study did
NCT04070079 · University Health Network, Toronto
2019-01-29 – 2022-12-31 · Hepatitis B, Chronic
What this study did
NCT04850950 · The First Affiliated Hospital of Zhengzhou University
2021-04-26 – 2022-12-31 · Chronic Hepatitis B, Mother-to-Child Transmission, Safety, Efficacy, Hepatitis B Virus, Tenofovir Alafenamide Fumarate
What this study did
NCT03471624 · Stanford University
2018-05-01 – 2022-04-19 · Hepatitis B, Chronic
What this study did
NCT03695029 · National Taiwan University Hospital
2010-12-29 – 2021-12-31 · Hepatitis B Virus Infection
What this study did
NCT03798119 · Kaohsiung Medical University Chung-Ho Memorial Hospital
2019-02-25 – 2021-08-31 · Hepatitis B, Fibrosis and Cirrhosis of Liver
What this study did
NCT03241641 · Young-Suk Lim
2017-10-26 – 2021-03-25 · Chronic Hepatitis b
What this study did
NCT02957994 · Asian Pacific Liver Center at Coalition of Inclusive Medicine
2016-12-22 – 2017-11-01 · Hepatitis B
What this study did
Other / comorbidity
NCT05001672 · Taipei Veterans General Hospital, Taiwan
2021-08-15 – 2025-12-31 · HBV, Inflammatory Arthritis
What this study did
NCT05326971 · Jussi Sutinen
2023-01-19 – 2025-06-01 · HIV Infections, Weight Gain
What this study did
NCT04683341 · Kaohsiung Medical University Chung-Ho Memorial Hospital
2020-09-01 – 2025-04-01 · HBV
What this study did
NCT04290936 · Taipei Veterans General Hospital, Taiwan
2020-10-16 – 2024-12-31 · HCC Patients After Curative Treatment With Low HBV Viral Load
What this study did
NCT05063071 · Fudan University
2021-07-29 – 2022-12-29 · HBV, POST LIVER TRANSPLANT
What this study did
NCT04391608 · Mahidol University
2019-11-09 – 2022-07-31 · Renal Insufficiency, Tenofovir
What this study did
NCT02957864 · Erasmus Medical Center
2016-10 – 2020-09 · Renal Insufficiency,Chronic, Hiv, Therapeutic Agent Toxicity
What this study did
NCT03126370 · University of Colorado, Denver
2018-01-08 – 2019-10-01 · Hepatitis C, HIV Coinfection
What this study did
Early phase / not applicable (14)
Chronic Hepatitis B
NCT06707922 · Xiamen Amoytop Biotech Co., Ltd.
2022-03-18 – 2029-07-31 · Chronic Hepatitis B
What this study did
NCT07253220 · Sun Yat-sen University
2025-12-01 – 2028-09-30 · Hepatitis B, Hepatocellular Carcinoma (HCC)
What this study did
NCT06947356 · Guangzhou 8th People's Hospital
2025-05-03 – 2028-05-01 · Hepatitis B
What this study did
NCT05195450 · Institute of Liver and Biliary Sciences, India
2022-02-23 – 2027-12-31 · Non-cirrhotic, Chronic Hepatitis B
What this study did
NCT04231565 · Third Affiliated Hospital, Sun Yat-Sen University
2020-06-04 – 2027-07-01 · Hepatitis B Virus
What this study did
NCT05490836 · Huashan Hospital
2022-09-01 – 2026-09-30 · Chronic Hepatitis B
What this study did
NCT04195074 · Third Affiliated Hospital, Sun Yat-Sen University
2019-01-01 – 2024-12-31 · Chronic Hepatitis b
What this study did
NCT05721300 · Zhongshan Hospital (Xiamen), Fudan University
2023-02-10 – 2024-12-31 · Hepatocellular Carcinoma, Chronic Hepatitis B
What this study did
NCT03920618 · Third Affiliated Hospital, Sun Yat-Sen University
2019-02-21 – 2024-12-31 · Hepatitis B, Acute-On-Chronic Liver Failure
What this study did
NCT04501224 · Third Affiliated Hospital, Sun Yat-Sen University
2020-08-03 – 2024-04-30 · Chronic Hepatitis b, Cirrhosis Due to Hepatitis B
What this study did
NCT04196998 · Third Affiliated Hospital, Sun Yat-Sen University
2019-01-01 – 2023-12 · Hepatitis B, Compensated Cirrhosis
What this study did
Other / comorbidity
NCT06773754 · National Taiwan University Hospital
2022-06-14 – 2025-12-31 · Virally Suppressed People With HIV
What this study did
NCT04703465 · RenJi Hospital
2021-04-01 – 2024-04-01 · HBV, Liver Transplant Disorder
What this study did
NCT05453448 · Xiangya Hospital of Central South University
2022-05-01 – 2022-05-30 · Antiviral Drugs
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Chronic Hepatitis B
NCT07307586 · Zhigang Ren
2025-09-01 – 2027-12-31 · Chronic Hepatitis B, Azvudine
What this study did
Other / comorbidity
NCT03446573 · ViiV Healthcare
2018-01-18 – 2022-05-03 · HIV Infections
What this study did
Phase 2 (1)
Other / comorbidity
NCT03549689 · Philip Grant
2019-08-01 – 2021-07-01 · HIV/AIDS, HIV-1-infection, Osteopenia
What this study did
Phase 1 (1)
Chronic Hepatitis B
NCT04629976 · Nucorion Pharmaceuticals, Inc.
2021-01-12 – 2022-12-28 · Chronic Hepatitis B
What this study did
Phase 4 (1)
Chronic Hepatitis B
NCT03604016 · IlDong Pharmaceutical Co Ltd
2018-09-23 – 2020-07-30 · Hepatitis B
What this study did
Studied as part of a combination product (131)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (42)
Chronic Hepatitis B
NCT02071082 · Gilead Sciences
2014-02-25 – 2016-10-26 · HIV, HBV
What this study did
Other / comorbidity
NCT06630286 · Gilead Sciences
2024-10-09 – 2030-08 · HIV-1-infection
What this study did
NCT07711223 · Jiangsu Aidea Pharmaceutical Group Co., Ltd.
2025-11-07 – 2028-12-31 · Infection, Human Immunodeficiency Virus
What this study did
NCT07075146 · José Antonio Mata Marín
2025-05-05 – 2028-08-01 · HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity
What this study did
NCT04925752 · Gilead Sciences
2021-06-28 – 2028-08 · Pre-Exposure Prophylaxis of HIV Infection
What this study did
NCT05813964 · ANRS, Emerging Infectious Diseases
2024-06-05 – 2028-05-31 · HIV/AIDS
What this study did
NCT04994509 · Gilead Sciences
2021-08-30 – 2028-01 · Pre-Exposure Prophylaxis of HIV Infection
What this study did
NCT04652700 · Merck Sharp & Dohme LLC
2021-03-15 – 2023-08-04 · HIV Preexposure Prophylaxis
What this study did
NCT05457530 · Prism Health North Texas
2022-08-01 – 2023-05-03 · Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
What this study did
NCT03727152 · The HIV Netherlands Australia Thailand Research Collaboration
2019-05-01 – 2023-04-04 · HIV
What this study did
NCT04155554 · Azienda Ospedaliera Universitaria Senese
2020-01-29 – 2021-07 · HIV-1-infection
What this study did
NCT04405271 · Hospital Italiano de Buenos Aires
2020-07-31 – 2020-11-15 · Healthcare Workers, COVID-19, SARS-CoV 2
What this study did
NCT03048422 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-01-19 – 2020-10-03 · HIV Infections
What this study did
NCT02469246 · Gilead Sciences
2015-06-29 – 2019-03-13 · HIV-1 Infection
What this study did
NCT02121795 · Gilead Sciences
2014-05-06 – 2019-03-01 · HIV-1 Infection
What this study did
NCT01797445 · Gilead Sciences
2013-03-12 – 2018-10-03 · HIV, HIV Infections
What this study did
NCT01705574 · Gilead Sciences
2012-10-24 – 2018-09-06 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
NCT01818596 · Gilead Sciences
2013-03-27 – 2018-07-18 · HIV, HIV Infections
What this study did
NCT02660905 · Ottawa Hospital Research Institute
2016-04 – 2018-06 · Human Immunodeficiency Virus, Hepatitis C, Chronic
What this study did
NCT01780506 · Gilead Sciences
2012-12-26 – 2017-09-06 · HIV, HIV Infections
What this study did
Phase 2/3 (9)
Other / comorbidity
NCT07266831 · Merck Sharp & Dohme LLC
2025-12-18 – 2031-12-18 · Human Immunodeficiency Virus Type 1 (HIV-1) Infection
What this study did
NCT02881320 · Gilead Sciences
2016-09-21 – 2027-06 · HIV-1 Infection
What this study did
NCT02016924 · Gilead Sciences
2014-01-16 – 2027-03 · Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
What this study did
NCT06613685 · Gilead Sciences
2024-10-21 – 2026-03-16 · HIV-1-infection
What this study did
NCT05140954 · University of Washington
2023-04-10 – 2023-12-19 · HIV Infections
What this study did
NCT02276612 · Gilead Sciences
2014-12-03 – 2017-10-23 · HIV
What this study did
Phase 2 (16)
Other / comorbidity
NCT07202546 · ViiV Healthcare
2026-02-11 – 2032-07-09 · HIV Infections
What this study did
NCT06891066 · Merck Sharp & Dohme LLC
2025-04-14 – 2031-09-30 · Human Immunodeficiency Virus Type 1 (HIV-1) Infection
What this study did
NCT07871552 · The University of Texas Health Science Center, Houston
2026-10-30 – 2028-10-15 · Epigenetic Aging
What this study did
NCT05052996 · Gilead Sciences
2021-10-05 – 2028-03 · HIV-1 Infection
What this study did
NCT06338826 · ANRS, Emerging Infectious Diseases
2025-02-01 – 2027-09-30 · HIV Infections, HBV Coinfection
What this study did
NCT05993767 · PENTA Foundation
2024-12-11 – 2026-01-20 · HIV Infection
What this study did
NCT02859558 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2017-01-24 – 2025-04-16 · HIV-1 Infection
What this study did
NCT04066881 · MRC/UVRI and LSHTM Uganda Research Unit
2020-12-15 – 2024-12-31 · HIV Infections
What this study did
NCT05458765 · Eastern Virginia Medical School
2022-06-21 – 2024-07-25 · Acceptability of Health Care, Adherence, Medication
What this study did
NCT04483674 · Anna Cruceta
2020-12-04 – 2023-06 · HIV Primary Infection
What this study did
NCT04493216 · ViiV Healthcare
2020-11-18 – 2023-05-29 · HIV Infections
What this study did
NCT01497899 · Gilead Sciences
2011-12-28 – 2016-08-22 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
NCT02556333 · National Institute of Allergy and Infectious Diseases (NIAID)
2015-09-16 – 2016-08-16 · HIV
What this study did
NCT01565850 · Gilead Sciences
2012-04 – 2014-02 · Acquired Immunodeficiency Syndrome, HIV Infections
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03251144 · University of California, Los Angeles
2019-04-01 – 2021-07-01 · HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
What this study did
Phase 1 (22)
Other / comorbidity
NCT07939529 · National Institute of Allergy and Infectious Diseases (NIAID)
2028-02-01 – 2030-10-26 · HIV Viremia
What this study did
NCT07055451 · Gilead Sciences
2025-08-12 – 2028-03 · HIV-1-infection
What this study did
NCT07349758 · Johns Hopkins University
2026-01-06 – 2028-01-01 · Healthy Volunteer, HIV Prevention
What this study did
NCT07210528 · National University Hospital, Singapore
2025-06-30 – 2026-09 · Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
What this study did
NCT07532304 · Merck Sharp & Dohme LLC
2026-05-11 – 2026-07-23 · Healthy
What this study did
NCT04820933 · University of Texas Southwestern Medical Center
2024-03-01 – 2025-12-01 · HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
What this study did
NCT06278389 · Jiangsu Aidea Pharmaceutical Group Co., Ltd.
2024-01-24 – 2024-05-20 · Healthy Adult Participants
What this study did
NCT04950530 · Chelsea and Westminster NHS Foundation Trust
2022-12-22 – 2024-02-29 · HIV-1-infection
What this study did
NCT05489406 · Radboud University Medical Center
2022-10-06 – 2023-11-30 · Hiv
What this study did
NCT04302896 · Rhonda Brand
2020-08-31 – 2021-09-30 · Medication Adherence, HIV
What this study did
NCT04853524 · Janssen Research & Development, LLC
2021-05-06 – 2021-07-30 · Healthy
What this study did
NCT02962739 · University of Colorado, Denver
2016-03 – 2019-05-22 · Healthy Volunteers
What this study did
NCT03836729 · ViiV Healthcare
2019-02-11 – 2019-04-30 · HIV Infections
What this study did
NCT03186482 · St. Stephens Clinical Research
2017-06-01 – 2018-01-10 · HIV
What this study did
NCT02904369 · CONRAD
2016-10-06 – 2017-11-21 · HIV
What this study did
NCT03092206 · Technical University of Munich
2017-04-18 – 2017-07-28 · Insulin Resistance
What this study did
NCT02578550 · Janssen Sciences Ireland UC
2015-11 – 2016-02 · Healthy
What this study did
NCT02475135 · Janssen Sciences Ireland UC
2015-06-01 – 2015-08-14 · Healthy
What this study did
Phase 4 (37)
Chronic Hepatitis B
NCT03797014 · University of Maryland, Baltimore
2019-04-30 – 2023-05-05 · HIV-1-infection, Hepatitis B
What this study did
Other / comorbidity
NCT06337032 · Gilead Sciences
2024-08-27 – 2034-03 · HIV-1-infection
What this study did
NCT07031063 · Instituto Mexicano del Seguro Social
2025-04-01 – 2028-12-01 · HIV Infection, Metabolic Syndrome, Antiretroviral Treatment
What this study did
NCT06374758 · University of Missouri-Columbia
2024-04-29 – 2027-08-09 · HIV Infections, ART, Noncompliance, Patient
What this study did
NCT06375304 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2024-05-01 – 2027-05-01 · HIV Infections
What this study did
NCT07678268 · Instituto Mexicano del Seguro Social
2025-07-10 – 2026-12-10 · HIV Infection, Antiretroviral Therapy, Lentivirus Infections
What this study did
NCT05898841 · Fundacion SEIMC-GESIDA
2023-05-26 – 2025-07-07 · HIV Infections, Fatty Liver Disease
What this study did
NCT04884139 · Fundacion SEIMC-GESIDA
2021-07-14 – 2025-03-13 · HIV-1-infection
What this study did
NCT04636437 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2021-07-27 – 2024-10-18 · HIV Infections
What this study did
NCT04530630 · Weill Medical College of Cornell University
2020-11-09 – 2024-08-28 · HIV Infections, Renal Transplant Rejection
What this study did
NCT04993872 · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
2022-09-29 – 2024-07-01 · HIV-infected Patient Kidney Transplant Recipient
What this study did
NCT05405751 · Fundacion SEIMC-GESIDA
2022-07-04 – 2024-06-12 · HIV Infections
What this study did
NCT04388904 · The Crofoot Research Center, Inc.
2021-09-01 – 2024-04-05 · HIV-1-infection
What this study did
NCT03916328 · MU-JHU CARE
2019-12-03 – 2024-03-31 · Bone Loss
What this study did
NCT05243602 · University of Nairobi
2022-02-01 – 2024-03-18 · HIV-1-infection
What this study did
NCT04616963 · University of California, San Diego
2019-10-24 – 2024-01-31 · Hiv, Hormone Therapy
What this study did
NCT04585737 · Charlotte-Paige Rolle, MD
2020-10-05 – 2023-08-10 · HIV I Infection
What this study did
NCT04249037 · University of Colorado, Denver
2020-12-15 – 2023-07-01 · HIV/AIDS
What this study did
NCT05147740 · Tulika Singh, MD
2021-07-01 – 2022-12 · HIV-1-infection
What this study did
NCT04311957 · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
2020-09-01 – 2022-11-30 · HIV-1-infection, Antiretroviral Therapy
What this study did
NCT04222283 · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
2020-08-17 – 2022-06-30 · HIV Infections
What this study did
NCT03998176 · University of Nebraska
2019-10-09 – 2022-04-01 · HIV-1-infection
What this study did
NCT05606055 · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
2020-12-01 – 2022-03-03 · HIV-1-infection
What this study did
NCT04538040 · Quest Clinical Research
2019-12-19 – 2021-11-11 · HIV-1-infection
What this study did
NCT04132674 · Vancouver Infectious Diseases Centre
2018-11-26 – 2020-12-31 · Human Immunodeficiency Virus I Infection, Drug Use
What this study did
NCT03348163 · The University of Texas Health Science Center, Houston
2018-06-06 – 2020-12-15 · HIV Infections
What this study did
NCT03502005 · Midland Research Group, Inc.
2018-03-01 – 2019-12-30 · Human Immunodeficiency Virus
What this study did
NCT02771054 · Göteborg University
2016-05-02 – 2018-07-15 · HIV
What this study did
NCT03350672 · Philadelphia Fight
2017-11-16 – 2018-05-01 · Hiv
What this study did
Early phase / not applicable (4)
Other / comorbidity
NCT04593680 · Thai Red Cross AIDS Research Centre
2022-01-24 – 2025-10-01 · Drug Interaction
What this study did
NCT04712058 · National Taiwan University Hospital
2021-01-20 – 2023-01-31 · HIV Infections
What this study did
NCT03512964 · Johns Hopkins University
2016-11-29 – 2020-09-13 · Human Immunodeficiency Virus
What this study did
NCT03405194 · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
2018-05-01 – 2020-07-01 · HIV/AIDS
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Chronic Hepatitis B
NCT07095855 · Shanghai Zhimeng Biopharma, Inc.
2025-08 – 2030-01 · Chronic Hepatitis B
What this study did
Phase 2 (4)
Chronic Hepatitis B
NCT05404919 · University of Pennsylvania
2022-09-06 – 2024-08-01 · Lung Transplant, Hepatitis B
What this study did
NCT05244057 · Shanghai HEP Pharmaceutical Co., Ltd.
2022-08-23 – 2024-06-24 · Chronic Hepatitis B
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Hepatitis B: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tenofovir Alafenamide (Vemlidy): this drugApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Entecavir (Baraclude)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Adefovir Dipivoxil (Hepsera)DiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Telbivudine (Tyzeka)Discontinued—HBV polymerase (reverse transcriptase)Partial signal
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed

Upcoming events

(17 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow tenofovir alafenamide (Vemlidy) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 4Chronic Hepatitis BNot yet recruiting
Est. primary completion 2026-12-01 · NCT06221657 · CT.gov ↗
What to watch
2027 (7)
February 2027 (1)
Phase 1Chronic Hepatitis BNot yet recruiting
Est. primary completion 2027-02 · NCT07946757 · CT.gov ↗
What to watch
March 2027 (1)
Phase 4Chronic Hepatitis BEnrolling by invitation
Est. primary completion 2027-03-30 · NCT07668934 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2/3Chronic Hepatitis BActive not recruiting
Est. primary completion 2027-06-30 · NCT07203118 · CT.gov ↗
What to watch
September 2027 (1)
Early phase / not applicableChronic Hepatitis BNot yet recruiting
Est. primary completion 2027-09-30 · NCT07253220 · CT.gov ↗
What to watch
December 2027 (3)
Phase 4Chronic Hepatitis BRecruiting
Est. primary completion 2027-12-31 · NCT03933384 · CT.gov ↗
What to watch
Phase 4Chronic Hepatitis BRecruiting
Est. primary completion 2027-12-31 · NCT04939441 · CT.gov ↗
What to watch
Early phase / not applicableChronic Hepatitis BRecruiting
Est. primary completion 2027-12-31 · NCT05195450 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 2Healthy Volunteer, Weight Gain, Metabolic Effects, Integrase Strand Transfer InhibitorsRecruiting
Est. primary completion 2028-01-31 · NCT05652478 · CT.gov ↗
What to watch
May 2028 (1)
Early phase / not applicableChronic Hepatitis BRecruiting
Est. primary completion 2028-05-01 · NCT06947356 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Chronic Hepatitis BNot yet recruiting
Est. primary completion 2028-09 · NCT07797231 · CT.gov ↗
What to watch
December 2028 (2)
Phase 4Chronic Hepatitis BEnrolling by invitation
Est. primary completion 2028-12-01 · NCT07542951 · CT.gov ↗
What to watch
Phase 4Chronic Hepatitis BNot yet recruiting
Est. primary completion 2028-12-31 · NCT07258251 · CT.gov ↗
What to watch
2029 (2)
May 2029 (1)
Early phase / not applicableChronic Hepatitis BEnrolling by invitation
Est. primary completion 2029-05-31 · NCT06707922 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3HIV InfectionNot yet recruiting
Est. primary completion 2029-06 · NCT07792096 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 4Chronic Hepatitis BActive not recruiting
Est. primary completion 2031-12-31 · NCT03753074 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 1Chronic Hepatitis BNot yet recruiting
Est. primary completion 2034-12-31 · NCT07553767 · CT.gov ↗
What to watch

See the full readout calendar ↗